Jcr Pharmaceuticals Co., Ltd. · TSE:4552
Jcr Pharmaceuticals — Investor Presentation (May 2020)
26 slides from Jcr Pharmaceuticals's investor presentation, May 18, 2020
Slide 1: Midterm Business Plan for 2020-2022 “REVOLUTION”
Midterm Business Plan for 2020-2022 “REVOLUTION” May 18 th, 2020 JCR Pharmaceuticals Co., Ltd. Toru Ashida, Senior Executive Director, Executive Director, Sales Division, In charge of Corporate Strategy Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All forward-looking statements regarding our plans, outlook, strategy and future performance are based on judgments derived
Slide 3: Contents
Contents General Overview of “HIYAKU” (Previous Business Plan for FY2015-FY2019) Mid- to Long-Term Management Vision “Toward 2030” – Corporate Philosophy – Mid- to Long-Term Management Vision – Core Values – History of Growth and Characteristics of Our R&D – Potential of Our Basic Technology – R&D D
Slide 4: General Overview of “HIYAKU”
General Overview of “HIYAKU” (Previous Business Plan for FY2015-FY2019) 3
Slide 5: Achievements during Previous Business Plan
Achievements during Previous Business Plan • Feasibility Study Agreement with Sumitomo • Approval and Launch of TEMCELL® HS inj. Dainippon Pharma and Eisai for J-Brain Cargo® • Research agreement with PeptiDream FY2015 • Application for Marketing Authorization of GROWJECT® Liquid Formulation • Offic
Slide 6: Achievements during Previous Business Plan: FY2015 to FY2019
Achievements during Previous Business Plan FY2015 to FY2019 Sales ： ¥17.4 bil to ¥24.7 bil Operating income ： ¥2.15 bil to ¥3.24 bil Operating income to sales ： 12.3% to 13.1% 5 Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Slide 7: Achievements during Previous Business Plan
Achievements during Previous Business Plan Num. Employees Duration of FY Avg. Age Avg. Annual Salary (Non-consolidated) Service As of Mar. 31,2019 2019 654 41.4 8.9 ¥8.3 mil No. of Employees ： 654 2018 613 41.4 8.8 ¥8.3 mil Avg. age ： 41.4 2017 540 41.6 9.0 ¥8.2 mil Avg. salary ： ¥8.3 mil 2016 522 4
Slide 8: JCR achieved substantial results for the next stage during “HIYAKU”
General Overview of Previous Business Plan JCR achieved substantial results for the next stage during “HIYAKU” with “Speed First” spirit. – Approval and launch of TEMCELL® HS inj. ,GROWJECT® liquid formulation, Agalsidase beta BS I.V. infusion and Darbepoetin alfa BS injection – On-track progress of
Slide 9: Sustainability
Sustainability Through our business activities centered on the field of pediatric rare diseases, we will strive to “contribute to unmet medical needs” and enhance activities related to “Rare Diseases: RD, ESG”. Initiatives Rare Diseases (RD) Society (S) Conduct awareness-raising activities Maintain
Slide 10: Mid-to Long-Term Management Vision “Toward 2030”
Mid-to Long-Term Management Vision “Toward 2030” Research-Oriented Specialty Pharma with Global Exposure 9 Core Value “Team JCR”
Slide 11: Corporate Philosophy
Corporate Philosophy JCR is committed to challenging rare diseases by uniting our R&D and manufacturing capabilities to contribute to the patients and children around the医薬品を通して人々の健康に貢献する world. Contributing towards people’s healthcare through pharmaceutical products Reliability Confidence Belief We
Slide 12: Mid-to Long-Term Management Vision “Toward 2030”
Mid-to Long-Term Management Vision ”Toward 2030” Our Goal Research-oriented specialty pharma with global exposure Corporate Image in Detail ◎Global specialty pharma in the rare disease arena ◎Continuing challenges to create “one step beyond” technologies based on our unique technology platform such
Slide 13: Core Values: “Team JCR” is our source of values
Core Values “Team JCR” is our source of values. JCR’s growth has been driven by “R&D” and “Manufacturing” capabilities. Each and every person who has been inspired by JCR’s philosophy has founded a robust business platform and created its various cutting-edge technologies including J-Brain Cargo® wh
Slide 14: History of Growth and Characteristics of Our R&D
History of Growth History and Characteristics of Our “R&D” Purification technology cultivated since JCR's foundation, growth hormone business entered since 1985, and recombinant DNA and regenerative medical technologies engaged since 2000 contributed to the steady growth of JCR to date. From human-d
Slide 15: JCR’s “R&D”
JCR’s “R&D” Steady R&D activity with robust business base from growth hormone revenue (since 1993) . Purification technology as our fundamental technology starting from urokinase business, cultivated through over 20 years of R&D using human-derived materials such as urine and blood. Recombination DN
Slide 16: JCR’s Potential - J-Brain Cargo -
JCR’s Potential -J-Brain Cargo®- Effective drugs are desired for lysosomal storage diseases, a group of ultra-rare diseases. With the development of our drug candidates utilizing JCR’s proprietary Blood Brain Barrier (BBB)-penetrating technology, JCR expects potential expansion of market penetration
Slide 17: R&D Direction
R&D Direction Our current antibody-based J-Brain Cargo® technology is more amenable to target proteins rather than small molecules and nucleic acids. JCR is now investigating new modalities to enable those moieties to penetrate BBB by expanding the technological possibilities of J-Brain Cargo®, a tr
Slide 18: R&D Target Timeline
R&D Target Timeline JCR is taking on challenges to create and deliver first-in-class drugs from Japan with our proprietary technologies. ＊Only in-house R&D activities are listed. 17 Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Slide 19: Midterm Business Plan for 2020-2022 “REVOLUTION”
Midterm Business Plan for 2020-2022 “REVOLUTION” 18
Slide 20: Keyword
Keyword By uniting our “Team JCR” capabilities, JCR will pursue our “REVOLUTION” in quality and quantity for business toward 2030. 19 Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Slide 21: “REVOLUTION”: Important Business Challenges
“REVOLUTION”：Important Business Challenges JCR will be addressing the 6 important business challenges below in anticipation of our full-fledged globalization. Top priority business challenge in anticipation of growing presence of JCR in the rare disease area [1] Qualitative and quantitative reorgani
Slide 22: REVOLUTION: Guidance
REVOLUTION：GUIDANCE Sales and Operating income in FY2022 Sales : ¥32〜36 billion Operating income : ¥7〜10 billion (To target steady growth with year-to-year rise) R&D expenditures Around 20% of sales (Beyond 20% could be allocated, if required) Dividend Ratio Around 30% (Under a stable dividend polic
Slide 23: JCR’s Sustainability: Basic Policy during “REVOLUTION”
JCR’s Sustainability：Basic Policy during “REVOLUTION” JCR will commit to development of a sustainable society through our corporate philosophy, “Contributing towards people’s healthcare through pharmaceutical products”. Basis for Realizing medical care for those living with rare diseases value creat
Slide 24: JCR’s Sustainability: Efforts during “REVOLUTION”
JCR’s Sustainability：Efforts during “REVOLUTION” JCR will commit to expansion of sustainability efforts in quality and quantity in order to become a global specialty pharma company in the rare disease arena. Target Realization of sustainability through activities based on RD・E・S・G Direction Rare Dis
Slide 25: JCR’s Sustainability: Efforts during “REVOLUTION” E S G
JCR’s Sustainability：Efforts during “REVOLUTION” JCR will commit to expansion of sustainability efforts in quality and quantity in order to become a global specialty pharma company in the rare disease arena. Target Realization of sustainability through activities based on RD・E・S・G Direction E Enviro
Slide 26: Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.
JCR Pharmaceuticals — Investor Presentation (May 2020) on 6ix